Bibliographic Info
GuidelineWHO Guidelines for malaria, 14 March 2023
Year of Publication2023
Issuing InstitutionWHO
Recommendation
Status
Maintained
Recommended in favor
Strong
Certainty of evidence
High
Children and adults with uncomplicated P. falciparum malaria should be treated with one of the following ACTs*:
- artemether-lumefantrine (AL)
- artesunate-amodiaquine (AS+AQ)
- artesunate-mefloquine (ASMQ)
- dihydroartemisinin-piperaquine (DHAP)
- artesunate + sulfadoxine-pyrimethamine (AS+SP)
- artesunate-pyronaridine (ASPY) (2022)
*Artesunate + sulfadoxine-pyrimethamine and artesunate-pyronaridine are not recommended for use in the first trimester of pregnancy. For details of treatment using ACTs in the first trimester of pregnancy, see 5.2.1.4.1 below.
Notes and Remarks
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guidelines for malaria, 25 November 2022.
Year2022
InstitutionWorld Health Organization
Guideline
WHO guidelines for malaria, 16 October 2023.
Year2023
InstitutionWorld Health Organization
Guideline
WHO guidelines for malaria, 30 November 2024.
Year2024
InstitutionWHO